AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe Products in US

 AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe Products in US

AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe Products in US

Shots:

  • Under Dzuveo agreement, AcelRx to receive ~$55M as an up front and commercial milestones in addition to 35% to 45% revenue share on net sales of Dzuveo. AcelRx will manufacture and supply Dzuveo while Aguettant gets the right to commercialize Dzuveo in the EU
  • As per second agreement, Aguettant has the right to receive ~$24M as commercial milestone at ~$60M annual sales levels in addition to 40 to 45% revenue share on net sales of the two pre-filled syringe products, following their approval in the US
  • AcelRx obtains the rights to file NDAs and commercialize two pre-filled syringe product in the US

Click here to­ read the full press release/ article | Ref: PR Newswire | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post